Select Publications
Journal articles
2021, 'Australian Gonococcal Surveillance Programme Annual Report, 2020', COMMUNICABLE DISEASES INTELLIGENCE, 45, http://dx.doi.org/10.33321/cdi.2021.45.24
,2021, 'Australian Gonococcal Surveillance Programme Annual Report, 2020', Communicable diseases intelligence (2018), 45, http://dx.doi.org/10.33321/cdi.2021.45.24
,2021, 'Is gentamicin a viable therapeutic option for treating resistant Neisseria gonorrhoeae in New South Wales?', Communicable diseases intelligence (2018), 45, http://dx.doi.org/10.33321/cdi.2021.45.12
,2021, 'Enhanced molecular surveillance in response to the detection of extensively resistant gonorrhoea in Australia', Journal of Antimicrobial Chemotherapy, 76, pp. 270 - 271, http://dx.doi.org/10.1093/JAC/DKAA402
,2020, 'Australian Gonococcal Surveillance Programme 1 July to 30 September 2020', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.96
,2020, 'Meningococcal Surveillance Australia Reporting period 1 July to 30 September 2020', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.95
,2020, 'Laboratory-based surveillance of clostridium difficile infection in australian health care and community settings, 2013 to 2018', Journal of Clinical Microbiology, 58, http://dx.doi.org/10.1128/JCM.01552-20
,2020, 'Travel associated microbial keratitis: is resistance a risk?', Travel Medicine and Infectious Disease, 38, http://dx.doi.org/10.1016/j.tmaid.2020.101903
,2020, 'Bacterial Ocular Surveillance System (BOSS) Sydney, Australia 2017-2018', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.86
,2020, 'Meningococcal Surveillance Australia Reporting period 1 April to 30 June 2020', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.81
,2020, 'Pediatric Microbial Keratitis: Experience From Tertiary Referral Centers in New South Wales, Australia', Pediatric Infectious Disease Journal, 39, pp. 883 - 888, http://dx.doi.org/10.1097/INF.0000000000002723
,2020, 'Australian Gonococcal Surveillance Programme: 1 April to 30 June 2020', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.74
,2020, 'Australian Gonococcal Surveillance Programme: 1 July to 30 September 2019', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.73
,2020, 'Developing target product profiles for Neisseria gonorrhoeae diagnostics in the context of antimicrobial resistance: An expert consensus', PLoS ONE, 15, http://dx.doi.org/10.1371/journal.pone.0237424
,2020, 'Australian Meningococcal Surveillance Programme annual report, 2019', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.62
,2020, 'Meningococcal Surveillance Australia Reporting period 1 January to 31 March 2020', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.65
,2020, 'Are sex norms the norm in gonococcal surveillance?', The Lancet Microbe, 1, pp. e143 - e144, http://dx.doi.org/10.1016/S2666-5247(20)30087-2
,2020, 'Microbial keratitis in Sydney, Australia: risk factors, patient outcomes, and seasonal variation', Graefe's Archive for Clinical and Experimental Ophthalmology, 258, pp. 1745 - 1755, http://dx.doi.org/10.1007/s00417-020-04681-0
,2020, 'Australian Gonococcal Surveillance Programme Annual Report, 2019', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.58
,2020, 'Australian Gonococcal Surveillance Programme, 1 January to 31 March 2020', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.61
,2020, 'Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2019', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.47
,2020, 'Meningococcal Surveillance Australia: Reporting period 1 July to 30 September 2019', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.50
,2020, 'Australian Gonococcal Surveillance Programme, 1 April to 30 June 2019', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.37
,2020, 'Australian Meningococcal Surveillance Programme annual report, 2018', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.10
,2020, 'Antimicrobial resistance trends in bacterial keratitis over 5 years in Sydney, Australia', Clinical and Experimental Ophthalmology, 48, pp. 183 - 191, http://dx.doi.org/10.1111/ceo.13672
,2020, 'Lessons learnt from ceftriaxone-resistant gonorrhoea in the UK and Australia', The Lancet Infectious Diseases, 20, pp. 276 - 278, http://dx.doi.org/10.1016/S1473-3099(20)30055-4
,2020, 'Australian Gonococcal Surveillance Programme 1 April to 30 June 2018', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.5
,2020, 'Australian Gonococcal Surveillance Programme 1 January to 31 March 2019', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.3
,2020, 'Australian Gonococcal Surveillance Programme Annual Report, 2018', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.4
,2020, 'Meningococcal Surveillance Australia: Reporting period 1 January to 31 March 2019', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2020.44.9
,2020, 'Suspected materno-fetal transmission of neisseria meningitidis serogroup w clonal complex 11 causing early- onset neonatal sepsis', Open Forum Infectious Diseases, 7, http://dx.doi.org/10.1093/ofid/ofaa039
,2020, 'Australian Gonococcal Surveillance Programme 1 April to 30 June 2017', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2019.44.7
,2020, 'Australian Gonococcal Surveillance Programme 1 January to 31 March 2017', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2019.44.8
,2020, 'Australian Gonococcal Surveillance Programme 1 July to 30 September 2017', COMMUNICABLE DISEASES INTELLIGENCE, 44, http://dx.doi.org/10.33321/cdi.2020.44.6
,2020, 'Australian Gonococcal Surveillance Programme 1 July to 30 September 2017', Communicable diseases intelligence (2018), 44, http://dx.doi.org/10.33321/cdi.2019.44.6
,2020, 'Meningococcal and pneumococcal carriage in Hajj pilgrims: Findings of a randomized controlled trial', Journal of Travel Medicine, 27, http://dx.doi.org/10.1093/JTM/TAAA032
,2020, 'The clinical and microbiological features and outcomes of fungal keratitis over 9 years in Sydney, Australia', Mycoses, 63, pp. 43 - 51, http://dx.doi.org/10.1111/myc.13009
,2019, 'Meningococcal Surveillance Australia: Reporting period 1 July to 30 September 2017.', Commun Dis Intell (2018), 43, http://dx.doi.org/10.33321/cdi.2019.43.62
,2019, 'Microbial Keratitis and Ocular Surface Disease: A 5-Year Study of the Microbiology, Risk Factors and Clinical Outcomes in Sydney, Australia', Current Eye Research, 44, pp. 1195 - 1202, http://dx.doi.org/10.1080/02713683.2019.1631852
,2019, 'Early-Onset Neonatal Sepsis and Antibiotic Use in Northeast Thailand', AMERICAN JOURNAL OF PERINATOLOGY, 36, pp. 1295 - 1303, http://dx.doi.org/10.1055/s-0038-1676829
,2019, 'Emergence and spread of ciprofloxacin-resistant Neisseria gonorrhoeae in New South Wales, Australia: lessons from history', Journal of Antimicrobial Chemotherapy, 74, pp. 2214 - 2219, http://dx.doi.org/10.1093/jac/dkz182
,2019, 'Australian Rotavirus Surveillance Program : Annual Report, 2017', COMMUNICABLE DISEASES INTELLIGENCE, 43, http://dx.doi.org/10.33321/cdi.2019.43.28
,2019, 'Evaluation of the ResistancePlus GC (beta) assay: A commercial diagnostic test for the direct detection of ciprofloxacin susceptibility or resistance in Neisseria gonorrhoeae', Journal of Antimicrobial Chemotherapy, 74, pp. 1820 - 1824, http://dx.doi.org/10.1093/jac/dkz108
,2019, 'Australian Gonococcal Surveillance Programme Annual Report, 2017', Communicable diseases intelligence (2018), 43, http://dx.doi.org/10.33321/cdi.2019.43.13
,2019, 'Systematic review and survey of Neisseria gonorrhoeae ceftriaxone and azithromycin susceptibility data in the Asia Pacific, 2011 to 2016', PLoS ONE, 14, http://dx.doi.org/10.1371/journal.pone.0213312
,2019, 'Genetic relatedness of ceftriaxone-resistant and highlevel azithromycin resistant Neisseria gonorrhoeae cases, United Kingdom and Australia, February to April 2018', Eurosurveillance, 24, http://dx.doi.org/10.2807/1560-7917.ES.2019.24.8.1900118
,2019, 'Long-term outcomes after group B streptococcus infection: A cohort study', Archives of Disease in Childhood, 104, pp. 172 - 178, http://dx.doi.org/10.1136/archdischild-2017-314642
,2019, 'Whole-genome sequencing as an improved means of investigating Neisseria gonorrhoeae treatment failures', Sexual Health, 16, pp. 500 - 507, http://dx.doi.org/10.1071/SH19012
,2019, 'World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): Review of new data and evidence to inform international collaborative actions and research efforts', Sexual Health, 16, pp. 412 - 425, http://dx.doi.org/10.1071/SH19023
,2019, 'Systematic review and survey of neisseria gonorrhoeae antimicrobial resistance data in the Asia Pacific, 2011 to 2016', Pathology, 51, pp. S136 - S136, http://dx.doi.org/10.1016/j.pathol.2018.12.395
,